Therapeutic Potential of Melatonin in Systemic Lupus Erythematosus
-
by Mouj Hijazi
January 8, 2026
-
3 min
6 Key Takeaways
-
1
Melatonin shows potential as adjunctive therapy for SLE and lupus nephritis.
-
2
Reduced serum malondialdehyde levels were observed in SLE patients with melatonin.
-
3
The study was a randomized, double-blind, placebo-controlled trial.
-
4
Genetic polymorphisms can impact SLE susceptibility.
-
5
Melatonin may reduce renal damage in lupus nephritis models.
-
6
Requires further research on dosing regimens and long-term effects.
Melatonin may serve as a valuable adjunctive treatment for systemic lupus erythematosus (SLE) and lupus nephritis, leveraging its antioxidant and anti-inflammatory attributes. A review by Hosseinzadeh et al. indicates that melatonin supplementation reduced harmful serum malondialdehyde in SLE patients, enhancing their antioxidant status. Moreover, the molecule's immunomodulatory effects and the role of specific genetic polymorphisms in SLE susceptibility were emphasized. Research revealed that melatonin significantly lessens renal damage in lupus nephritis models, highlighting its clinical importance in managing SLE complications.
Listen Tab content
